We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This insight paper looks at the impact of transport on health during and after the COVID-19 pandemic in Africa and South Asia
Steps for investigating and managing individuals who are suspected to be reinfected with SARS-CoV-2.
Consensus statement from the Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) for the Scientific Advisory Group for Emergencies (SAGE).
Modelled estimates of the SARS-CoV-2 (COVID-19) infection hospitalisation risk (IHR) and the infection fatality risk (IFR) in England, as well as an analysis of those attending work while sick with a self-reported respiratory illness (presenteeism) in England and Scotland over...
Paper prepared by the Academy of Medical Sciences (AMS) and the British Society for Immunology (BSI).
A study to gather vital data on COVID-19 this winter has been launched by the UK Health Security Agency (UKHSA) and the Office for National Statistics (ONS).
List of participants of SAGE and related sub-groups.
Analysis of the number of people in the UK who have tested positive for COVID-19 using the Coronavirus (COVID-19) Infection Survey. This survey is being delivered in partnership with University of Oxford, University of Manchester, UK Health Security Agency and...
The medicine regulators from Australia, Canada, Singapore, Switzerland and the United Kingdom (Access Consortium) have discussed the regulatory evidence requirements for COVID-19 vaccine approvals and considerations for post-market pharmacovigilance.
This brief is based on evidence from recent research programmes commissioned by DFID and the National Institute for Health Research
Attendance in education settings since Monday 23 March 2020 and early years settings since Thursday 16 April 2020.
When to pay tax or National Insurance on tests for COVID-19 and personal protective equipment (PPE).
This paper assesses the direct and indirect health impacts of COVID-19 on the population in England, with a focus on the emerging Omicron impacts.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).